F.R. Khuri
Departments of Thoracic/Head and Neck Medical Oncology
The University of Texas M.D. Anderson Cancer Center
Houston
USA
Name/email consistency: high
- Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. Khuri, F.R., Rigas, J.R., Figlin, R.A., Gralla, R.J., Shin, D.M., Munden, R., Fox, N., Huyghe, M.R., Kean, Y., Reich, S.D., Hong, W.K. J. Clin. Oncol. (2001)
- Emerging therapies in non-small-cell lung cancer. Khuri, F.R., Herbst, R.S., Fossella, F.V. Ann. Oncol. (2001)
- The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Khuri, F.R., Kim, E.S., Lee, J.J., Winn, R.J., Benner, S.E., Lippman, S.M., Fu, K.K., Cooper, J.S., Vokes, E.E., Chamberlain, R.M., Williams, B., Pajak, T.F., Goepfert, H., Hong, W.K. Cancer Epidemiol. Biomarkers Prev. (2001)
- Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. Khuri, F.R., Lotan, R., Kemp, B.L., Lippman, S.M., Wu, H., Feng, L., Lee, J.J., Cooksley, C.S., Parr, B., Chang, E., Walsh, G.L., Lee, J.S., Hong, W.K., Xu, X.C. J. Clin. Oncol. (2000)